Amyloid proteins are misfolded proteins that clump together into tough, insoluble fibers called fibrils. Normally, proteins fold into specific three-dimensional shapes to do their jobs. When certain proteins misfold, they can stack into rigid, thread-like structures that the body cannot easily break down. These fibril deposits build up in organs and tissues, and depending on which protein is involved and where the deposits land, they can cause a range of serious diseases collectively known as amyloidosis.
What Makes Amyloid Different From Normal Protein
The defining feature of amyloid is a structural pattern called cross-beta. In this arrangement, individual protein molecules stretch out into flat strands and line up side by side, linked by a dense network of hydrogen bonds along their backbones. These sheets then stack on top of one another to form long, narrow fibrils roughly 10 to 20 nanometers in diameter.
What makes this remarkable is that the cross-beta structure doesn’t depend much on which protein is doing the misfolding. Because the bonds holding the fibrils together run along the protein backbone (the part shared by all proteins, regardless of their specific sequence), amyloid fibrils formed by wildly different proteins end up looking and behaving in strikingly similar ways. They share nearly identical dimensions, physical properties, and even the way they bind diagnostic dyes. This is why amyloid from one disease looks so much like amyloid from another under a microscope.
How Amyloid Forms in Alzheimer’s Disease
The best-known amyloid protein is amyloid-beta, the peptide fragment that accumulates in the brains of people with Alzheimer’s disease. It starts with a larger molecule called amyloid precursor protein (APP), which sits in the membranes of brain cells. APP gets cut by two enzymes in sequence. The first enzyme clips APP at a specific site, releasing a large fragment and leaving a smaller piece still anchored in the membrane. A second enzyme then cuts that remaining piece, releasing the amyloid-beta fragment.
There is actually an alternative pathway where a different enzyme makes the first cut at a location that falls right in the middle of the amyloid-beta sequence, effectively destroying it. When this alternate route is taken, the final fragment produced is harmless. The balance between these two pathways helps determine how much amyloid-beta the brain produces. Once released, amyloid-beta fragments can begin sticking together, first forming small clumps called oligomers, then larger fibrils, and eventually the dense plaques visible on brain imaging.
How Amyloid Damages Cells
Amyloid-beta causes harm through several mechanisms at once. The protein fragments can interact directly with cell membranes, forming pore-like channels that allow calcium to flood into cells. This calcium overload disrupts normal cell signaling and can trigger cell death. Amyloid also damages mitochondria, the structures inside cells that generate energy, altering their shape and breaking apart their typical network-like organization.
Interestingly, the severity of synapse loss (the connections between brain cells) correlates more closely with cognitive decline in Alzheimer’s patients than the sheer number of plaques or tangles does. This suggests that smaller, soluble clusters of amyloid may be doing more damage than the large, visible deposits, and that the harm is happening at the level of cell-to-cell communication rather than simply from physical bulk.
Amyloidosis Beyond the Brain
Alzheimer’s gets the most attention, but amyloid deposits can affect almost any organ. The two most common forms of systemic amyloidosis involve different proteins entirely.
AL amyloidosis involves fragments of antibodies called immunoglobulin light chains, produced by abnormal plasma cells in the bone marrow. These misfolded light chains deposit most frequently in the kidneys, often causing a condition where large amounts of protein spill into the urine. The heart is the second most commonly affected organ, and involvement can also extend to nerves and skin.
ATTR amyloidosis involves transthyretin, a protein made primarily by the liver that normally carries thyroid hormone and vitamin A in the blood. In the wild-type form (not caused by a genetic mutation), transthyretin gradually becomes unstable with age and deposits mainly in the heart. In the hereditary form, mutations in the transthyretin gene accelerate misfolding. More than 150 different mutations have been identified. Some mutations primarily affect the heart, while others target peripheral nerves, causing progressive numbness and weakness in the hands and feet.
The most common hereditary mutation, responsible for about 70% of hereditary ATTR cases worldwide, causes a substitution at a single position on the transthyretin protein. Another variant is found in 3 to 4% of African Americans and is associated with heart disease. Certain mutations cluster in specific populations: one in Northern Ireland, another in Sicily, others in Mexico, France, and Taiwan.
Diagnosis: From Tissue Biopsy to Blood Tests
For decades, diagnosing amyloidosis required a tissue biopsy stained with a special dye called Congo red, which makes amyloid fibrils glow apple-green under polarized light. Brain amyloid in Alzheimer’s could only be confirmed through PET scans using radioactive tracers or, definitively, after death.
That is changing. A blood test measuring a specific form of a brain protein called p-tau217 can now detect amyloid buildup in the brain with 82% sensitivity and 86% specificity. This means the test correctly identifies amyloid in roughly 8 out of 10 people who have it, and correctly rules it out in about 86 out of 100 people who don’t. While not perfect, this kind of simple blood draw is far more accessible than a PET scan and is increasingly being used to screen patients with memory concerns.
Treatment Options
Treatment depends entirely on which type of amyloid is involved. For Alzheimer’s disease, newer antibody-based therapies target amyloid-beta plaques directly. In one large trial, an anti-amyloid antibody reduced brain amyloid burden by about 59 centiloids (a standardized measure of plaque density) compared to placebo over 18 months. Cognitive decline slowed by 27% compared to participants receiving a placebo. These are modest but measurable effects, and they represent the first treatments to alter the underlying biology of the disease rather than just managing symptoms.
For ATTR amyloidosis, treatments focus on stabilizing the transthyretin protein so it doesn’t misfold, or on reducing how much transthyretin the liver produces in the first place. These approaches have significantly improved outcomes. Prognosis varies widely depending on how advanced the disease is at diagnosis: patients with wild-type ATTR cardiac amyloidosis in the lowest-risk category have a median survival around 86 months (just over seven years), while those in the highest-risk group have a median survival of about 17 months.
Amyloid Isn’t Always Harmful
One of the more surprising facts about amyloid is that the body deliberately uses it for beneficial purposes. Not all amyloid is a sign of disease. In mammals, peptide hormones are stored inside secretory granules in an amyloid-like state, kept inert until they’re needed and then released in their active form. A highly toxic protein in a type of white blood cell called an eosinophil is safely sequestered in amyloid form to prevent it from damaging surrounding tissue.
Beyond storage, amyloid structures play roles in memory. In sea slugs, a protein involved in long-term memory formation adopts an amyloid-like state, essentially using the self-reinforcing nature of amyloid folding as a molecular memory switch. In bacteria, amyloid fibers called curli are key structural components of biofilms. In fungi, prion-like amyloid proteins function as a primitive immune system, passing information about threats from one generation to the next. Even the protective eggshell of silkworms relies on proteins in an amyloid state to shield the developing embryo from environmental hazards.
The capacity to form amyloid appears to be a fundamental property of protein chains, one that evolution has harnessed for constructive purposes in many organisms. Disease occurs when this process happens to the wrong protein, in the wrong place, without the body’s usual controls.